Genesis Therapeutics

Incyte and Genesis Molecular AI expanded their collaboration to build and deploy AI to discover molecules for targets selected by Incyte. The agreement supports large-scale foundation model training with Incyte’s proprietary experimental data.

The page describes protein-ligand structure prediction as a way to model how molecules bind flexible target proteins and potentially support faster, rational drug design.

Latest news, press, and publications from Genesis, including the Pearl launch and announcements with Gilead, Incyte, and NVIDIA.

The company uses AI in small-molecule drug discovery for severe diseases and lists roles in AI research, drug discovery, engineering, and operations.

Genesis CEO and co-founder Evan founded the company in 2019 to develop AI and simulation research from Vijay Pande’s lab at Stanford University. He developed PotentialNet, a physics-based ML framework for challenging, data-poor drug targets.

Greg is a partner at Menlo Ventures, investing in life science and healthcare teams, and previously spent 20 years as an executive and entrepreneur in life science and digital health. Greg co-founded BlueLight Therapeutics/Biodesy and PyrAmes.

Guido Appenzeller is an investor at Andreessen Horowitz focused on AI, infrastructure, open source technology, and silicon. He previously held technology and product leadership roles at Intel and Yubico.

James Watson is an Operating Partner in Bio + Health, leading business and corporate development in life sciences. James provides strategic, corporate development, and financing support and serves on the boards of three bio portfolio companies.

Genesis pairs AI researchers and simulation experts with drug hunters and is backed by AI and life science investors.

Reach Genesis for business development, media inquiries, or general questions. Offices in San Mateo, San Diego, and New York.

Genesis combines AI and drug hunters to discover small-molecule medicines, builds on Pearl and GEMS, and has partnered with Gilead and Incyte.

Incyte and Genesis Therapeutics enter a strategic AI-focused research collaboration to discover and develop novel small-molecule medicines. The companies will use Genesis’ GEMS platform to research, discover, and develop the medicines, and Genesis receives a $30 million upfront payment.

Feb 2025 · BioSpaceNews article

Gilead Sciences and Genesis Therapeutics enter a strategic collaboration to discover and develop novel small-molecule therapies using Genesis’ GEMS AI platform. The agreement gives Gilead exclusive development and commercialization rights to the novel therapies discovered and developed through this collaboration.

Sep 2024 · Gilead SciencesNews article

Genesis Therapeutics closes an oversubscribed $200 million Series B financing to advance its AI-enabled pipeline into clinical development. The financing will also support expansion of its GEMS platform against previously undruggable targets.

Aug 2023 · Pharm ExecNews article

Genesis Therapeutics completes a $52 million Series A financing to expand its AI-driven drug-discovery platform. Rock Springs Capital leads the round, with participation from Andreessen Horowitz, T. Rowe Price, Menlo Ventures, and Radical Ventures.

Dec 2020 · BioSpaceNews article